Naimish Patel - 03 Apr 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Medical Officer
Signature: /s/ Naimish Patel
Issuer symbol: CRSP
Transactions as of: 03 Apr 2025
Net transactions value: +$49,704
Form type: 4
Filing time: 27 Jan 2026, 17:35:15 UTC
Previous filing: 18 Mar 2025
Next filing: 30 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Patel Naimish	Chief Medical Officer	C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON	/s/ Naimish Patel	27 Jan 2026	0002021679

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Purchase	$49,704	+1,508		$32.96	1,508	03 Apr 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The purchase of Common Shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,508 shares, with a subsequent sale of Common Shares at a price of $35.94 per share on May 29, 2025 pursuant to a mandatory "sell to cover" provision in an award agreement covering a restricted stock unit that vested on such date (and which was reported on a separate Form 4 filing dated May 30, 2025). The Reporting Person has agreed to pay to the Issuer $4,493.84, representing the full amount of the profit realized in connection with the short-swing transaction.

Content

The purchase of Common Shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,508 shares, with a subsequent sale of Common Shares at a price of $35.94 per share on May 29, 2025 pursuant to a mandatory "sell to cover" provision in an award agreement covering a restricted stock unit that vested on such date (and which was reported on a separate Form 4 filing dated May 30, 2025). The Reporting Person has agreed to pay to the Issuer $4,493.84, representing the full amount of the profit realized in connection with the short-swing transaction.